SOTAC (SOTAC) fundamentals
SOTAC is a listed company, part of the Pharmaceuticals sector, listed on the NSE as SOTAC (ISIN INE0O2D01012). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What SOTAC does
Sotac Pharmaceuticals Limited is an India-based pharmaceutical company. The Company's services include contract manufacturing, loan license, formulation and development (F & D) and research and development (R & D). It specializes in manufacturing a range of pharmaceutical products having a therapeutic portfolio including anti-diabetic, anti-psychotic, vitamins, minerals, iron, anti-cold, anti-allergic, dermatological products, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics (IP-Lactams & Non-IP-Lactams), anti-fungal and cephalosporin. It also manufactures nutraceuticals products and food products on contract-manufacturing basis. Its products are supplied across 14 states in India, and it exports its products to over 20 countries worldwide. Its subsidiaries include Sotac Healthcare Private Limited, Sotac Lifesciences Private Limited and Sotac Research Private Limited.
Valuation and market data
| Last close | ₹90.05 |
|---|---|
| Market capitalisation | ₹115 crore |
| Enterprise value | ₹128 crore |
| P/E (TTM) | 8.07 |
| Price to book | 1.97 |
| Price to sales (TTM) | 0.46 |
| Book value per share | ₹45.70 |
| Dividend yield | 11.10% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹102 crore | ₹9 crore | ₹6 crore | 0.00 |
| Mar 2025 | ₹101 crore | ₹11 crore | ₹9 crore | 7.26 |
| Mar 2024 | ₹104 crore | ₹4 crore | ₹4 crore | 3.90 |
| Mar 2023 | ₹78 crore | ₹4 crore | ₹2 crore | 3.58 |
| Mar 2021 | ₹49 crore | ₹-2 crore | ₹-2 crore | -10.28 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 72.8% |
|---|---|
| Foreign institutions (FII) | 16.8% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 10.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.